NTRX-07 is under clinical development by NeuroTherpia and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NTRX-07’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NTRX-07 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NTRX-07 overview

NTRX-07 is under investigation for the treatment of Alzheimer's disease complex regional pain syndrome (CRPS) and neuropathic pain. NTRX-07 administered through oral route. The drug candidate is a piperidine derivative. It targets cannabinoid (CB2) receptors.

Quick View NTRX-07 LOA Data

Report Segments
  • Innovator
Drug Name
  • NTRX-07
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Toxicology
Key Developers
  • Sponsor Company: NeuroTherpia
  • Originator: Cleveland Clinic Foundation
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.